

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Islatravir / Doravirine Formulation

Version 8.0 Revision Date: 05/19/2026 SDS Number: 3503196-00023 Date of last issue: 05/09/2026
Date of first issue: 10/08/2018

SECTION 1. IDENTIFICATION

Product name : Islatravir / Doravirine Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc
Address : 126 E. Lincoln Avenue
Rahway, New Jersey U.S.A. 07065
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Hazards for the product as supplied

Not a hazardous substance or mixture.

Other hazards

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.

Hazards associated with a change in physical form:

Conditions	Hazards
If small particles are generated during further processing, handling or by other means.	May form combustible dust concentrations in air.

GHS label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS No./Unique ID	Concentration (% w/w)	Trade secret
Doravirine	1338225-97-0*	>= 10 - <= 30	TSC
Cellulose	9004-34-6*	>= 7 - <= 13	TSC
Islatravir	865363-93-5*	> 0 - <= 0.1	TSC

* Indicates that the identifier is a CAS No.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Islatravir / Doravirine Formulation

Version 8.0 Revision Date: 05/19/2026 SDS Number: 3503196-00023 Date of last issue: 05/09/2026
Date of first issue: 10/08/2018

TSC- the actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.
- In case of skin contact : Wash with water and soap.
Get medical attention if symptoms occur.
- In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.
- Protection of first-aiders : No special precautions are necessary for first aid responders.
- Notes to physician : Treat symptomatically and supportively.
-

SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)
Halogenated compounds
Metal oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
- Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.
Use personal protective equipment.
-

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Islatravir / Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/09/2026
8.0	05/19/2026	3503196-00023	Date of first issue: 10/08/2018

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Islatravir / Doravirine Formulation

Version 8.0 Revision Date: 05/19/2026 SDS Number: 3503196-00023 Date of last issue: 05/09/2026
Date of first issue: 10/08/2018

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

inert or nuisance dust 50 Million particles per cubic foot
Value type (Form of exposure): TWA (total dust)
Basis: OSHA Z-3

15 mg/m³
Value type (Form of exposure): TWA (total dust)
Basis: OSHA Z-3

5 mg/m³
Value type (Form of exposure): TWA (respirable fraction)
Basis: OSHA Z-3

15 Million particles per cubic foot
Value type (Form of exposure): TWA (respirable fraction)
Basis: OSHA Z-3

Dust, nuisance dust and particulates 10 mg/m³
Value type (Form of exposure): PEL (Total dust)
Basis: CAL PEL

5 mg/m³
Value type (Form of exposure): PEL (respirable dust fraction)
Basis: CAL PEL

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Doravirine	1338225-97-0	TWA	500 ug/m3 (OEB2)	Internal
Cellulose	9004-34-6	TWA	10 mg/m ³	ACGIH
		TWA (Respirable)	5 mg/m ³	NIOSH REL
		TWA (total)	10 mg/m ³	NIOSH REL
		TWA (total dust)	15 mg/m ³	OSHA Z-1
		TWA (respirable fraction)	5 mg/m ³	OSHA Z-1
Islatravir	865363-93-5	TWA	10 µg/m3 (OEB 3)	Internal
		Wipe limit	100 µg/100 cm ²	Internal

Engineering measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Islatravir / Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/09/2026
8.0	05/19/2026	3503196-00023	Date of first issue: 10/08/2018

Personal protective equipment

- Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

- Appearance : powder
- Color : No data available
- Odor : No data available
- Odor Threshold : No data available
- pH : No data available
- Melting point/freezing point : No data available

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Islatravir / Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/09/2026
8.0	05/19/2026	3503196-00023	Date of first issue: 10/08/2018

Initial boiling point and boiling range : No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : Not applicable

Burning number : 5

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : Not applicable

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Minimum ignition energy : 10 - 30 mJ
Method: With inductance

30 - 100 mJ
Method: Without inductance

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Islatravir / Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/09/2026
8.0	05/19/2026	3503196-00023	Date of first issue: 10/08/2018

Particle characteristics
Particle size : 27.49 mm

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.
Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:

Doravirine:

Acute oral toxicity : LD50 (Rat): > 750 mg/kg
Remarks: No mortality observed at this dose.

(Rat): Method: Phototoxicity
Remarks: No evidence of phototoxicity was observed

LD50 (Dog): > 1,000 mg/kg
Remarks: No mortality observed at this dose.

LD50 (Mouse): > 450 mg/kg
Remarks: No mortality observed at this dose.

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Islatravir / Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/09/2026
8.0	05/19/2026	3503196-00023	Date of first issue: 10/08/2018

Islatravir:

Acute oral toxicity : LD50 (Rat): 70 - 200 mg/kg

Acute toxicity (other routes of administration) : TDLo (Rat): 50 mg/kg
Target Organs: Cardio-vascular system

TDLo (Monkey): 100 mg/kg
Target Organs: Cardio-vascular system

LD0 (Monkey): 12 mg/kg
Application Route: Subcutaneous
Remarks: No significant adverse effects were reported

Skin corrosion/irritation

Not classified based on available information.

Components:

Doravirine:

Remarks : No data available

Islatravir:

Species : reconstructed human epidermis (RhE)
Method : EpiDerm
Result : No skin irritation
Remarks : Not classified due to lack of data.

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Doravirine:

Remarks : No data available

Islatravir:

Result : No eye irritation
Method : Bovine cornea (BCOP)
Remarks : Not classified due to lack of data.

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Islatravir / Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/09/2026
8.0	05/19/2026	3503196-00023	Date of first issue: 10/08/2018

Components:

Doravirine:

Remarks : No data available

Islatravir:

Test Type : Local lymph node assay (LLNA)
Routes of exposure : Dermal
Species : Mouse
Result : Weak sensitizer
Remarks : May cause sensitization by skin contact.

Germ cell mutagenicity

Not classified based on available information.

Components:

Doravirine:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Rat
Cell type: Bone marrow
Application Route: Oral
Result: negative

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Islatravir:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells
Result: positive

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Islatravir / Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/09/2026
8.0	05/19/2026	3503196-00023	Date of first issue: 10/08/2018

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Rat
Application Route: Oral
Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Doravirine:

Species : Mouse
Application Route : Oral
Exposure time : 6 Months
Result : negative
Remarks : No significant adverse effects were reported

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Islatravir:

Remarks : Not classified due to lack of data.

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified based on available information.

Components:

Doravirine:

Effects on fertility : Test Type: Fertility
Species: Rat, male and female
Fertility: NOAEL: 450 mg/kg body weight
Result: No effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 450 mg/kg body weight
Result: No adverse effects.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Islatravir / Doravirine Formulation

Version 8.0 Revision Date: 05/19/2026 SDS Number: 3503196-00023 Date of last issue: 05/09/2026
Date of first issue: 10/08/2018

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 300 mg/kg body weight
Result: No adverse effects.

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

Islatravir:

Effects on fertility : Test Type: Fertility
Species: Rat, male and female
Application Route: Oral
General Toxicity Parent: LOAEL: 18 mg/kg body weight
Symptoms: reduced body weight gain
Result: No effects on fertility., No effects on reproduction parameters.
Remarks: Not classified due to lack of data.

Effects on fetal development : Test Type: Development
Species: Rat
Application Route: Oral
General Toxicity Maternal: NOAEL: 50 mg/kg body weight
Developmental Toxicity: NOAEL: 50 mg/kg body weight
Result: No effects on fetal development.

Test Type: Development
Species: Rabbit
Application Route: Oral
General Toxicity Maternal: NOAEL: 10 mg/kg body weight
Developmental Toxicity: NOAEL: 10 mg/kg body weight
Result: No effects on fetal development.

Test Type: Whole embryo culture assay
Species: Rat
Result: negative

Test Type: Embryonic Stem Cell Assay
Species: Mouse
Result: positive

STOT-single exposure

Not classified based on available information.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Islatravir / Doravirine Formulation

Version 8.0 Revision Date: 05/19/2026 SDS Number: 3503196-00023 Date of last issue: 05/09/2026
Date of first issue: 10/08/2018

Components:

Islatravir:

Routes of exposure : Oral
Target Organs : Cardio-vascular system
Assessment : May cause damage to organs.

STOT-repeated exposure

Not classified based on available information.

Components:

Islatravir:

Routes of exposure : Oral
Target Organs : Cardio-vascular system, Blood, Bone, Skin, Stomach
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Doravirine:

Species : Rat
NOAEL : 450 mg/kg
Application Route : Oral
Exposure time : 6 Months
Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : > 450 mg/kg
Application Route : Oral
Exposure time : 3 Months
Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : > 1,000 mg/kg
Application Route : Oral
Exposure time : 9 Months
Remarks : No significant adverse effects were reported

Cellulose:

Species : Rat
NOAEL : >= 9,000 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Islatravir:

Species : Rat
NOAEL : 10 mg/kg
LOAEL : 50 mg/kg
Application Route : Oral

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Islatravir / Doravirine Formulation

Version 8.0 Revision Date: 05/19/2026 SDS Number: 3503196-00023 Date of last issue: 05/09/2026
Date of first issue: 10/08/2018

Exposure time : 29 Days
Symptoms : blood effects, liver function change

Species : Rat
NOAEL : 3 mg/kg
LOAEL : 10 mg/kg
Application Route : Oral
Target Organs : Teeth
Symptoms : blood effects, liver function change
Remarks : The mechanism or mode of action may not be relevant in humans.

Species : Monkey
LOAEL : 10 - 75 mg/kg
Application Route : Oral
Target Organs : Stomach

Species : Monkey
NOAEL : 20 mg/kg
LOAEL : 75 mg/kg
Application Route : Oral
Exposure time : 28 Days
Target Organs : Cardio-vascular system
Symptoms : Increased heart rate

Species : Monkey
NOAEL : 5 mg/kg
LOAEL : 20 mg/kg
Application Route : Oral
Exposure time : 9 Months
Target Organs : Skin, Blood, Bone

Species : Monkey
NOAEL : 16.5 mg/kg
Application Route : Subcutaneous
Remarks : No significant adverse effects were reported

Species : Rat
NOAEL : 150 - 350 mg/kg
Application Route : Subcutaneous
Symptoms : hair loss, Swelling of tissue

Aspiration toxicity

Not classified based on available information.

Components:

Islatravir:

Not applicable

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Islatravir / Doravirine Formulation

Version 8.0 Revision Date: 05/19/2026 SDS Number: 3503196-00023 Date of last issue: 05/09/2026
Date of first issue: 10/08/2018

Experience with human exposure

Components:

Doravirine:

Ingestion : Symptoms: confusion, Headache, Dizziness, Nausea, Rash, abnormal dreams, flushing, Neurological disorders, mental depression

Islatravir:

Ingestion : Symptoms: Diarrhea, Nausea
Remarks: Well tolerated in clinical use

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Doravirine:

Toxicity to daphnia and other aquatic invertebrates : EC50 (Americamysis): 9.1 mg/l
Exposure time: 96 h

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 5.8 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

NOEC (Pseudokirchneriella subcapitata (green algae)): 5.8 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 1 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.38 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Islatravir / Doravirine Formulation

Version 8.0 Revision Date: 05/19/2026 SDS Number: 3503196-00023 Date of last issue: 05/09/2026
Date of first issue: 10/08/2018

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Islatravir:

Toxicity to algae/aquatic plants : EC50 (Raphidocelis subcapitata (freshwater green alga)): > 100 mg/l
End point: Growth rate
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Raphidocelis subcapitata (freshwater green alga)): 100 mg/l
End point: Growth rate
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 5.7 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 11 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209

NOEC: 1,000 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209

Persistence and degradability

Components:

Doravirine:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 2 %
Exposure time: 28 d

Cellulose:

Biodegradability : Result: Readily biodegradable.

Islatravir:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 50 %

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Islatravir / Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/09/2026
8.0	05/19/2026	3503196-00023	Date of first issue: 10/08/2018

Exposure time: 1.2 d
Method: OECD Test Guideline 314

Bioaccumulative potential

Components:

Doravirine:

Partition coefficient: n-octanol/water : log Pow: 2.08

Islatravir:

Partition coefficient: n-octanol/water : log Pow: -0.056
pH: 7

Mobility in soil

Components:

Doravirine:

Distribution among environmental compartments : log Koc: 2.86

Islatravir:

Distribution among environmental compartments : log Koc: 2.33
Method: OECD Test Guideline 106

Other adverse effects

Components:

Islatravir:

Results of PBT and vPvB assessment : Not persistent, bioaccumulative, and toxic (PBT).

Endocrine disrupting properties

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations. Do not dispose of waste into sewer.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Islatravir / Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/09/2026
8.0	05/19/2026	3503196-00023	Date of first issue: 10/08/2018

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Domestic regulation

49 CFR

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : No SARA Hazards

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

Cellulose, 2-hydroxypropyl methyl ether, acetate hydrogen butanedioate	71138-97-1
Doravirine	1338225-97-0
Croscarmellose sodium	74811-65-7
Cellulose	9004-34-6
Lactose	63-42-3

California Permissible Exposure Limits for Chemical Contaminants

Cellulose	9004-34-6
-----------	-----------

The ingredients of this product are reported in the following inventories:

AICS : not determined

CA. DSL : not determined

CN IECSC : not determined

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard




Islatravir / Doravirine Formulation

Version 8.0 Revision Date: 05/19/2026 SDS Number: 3503196-00023 Date of last issue: 05/09/2026
Date of first issue: 10/08/2018

SECTION 16. OTHER INFORMATION

Further information

NFPA 704:



HMIS® IV / CED:

HEALTH	/	0
FLAMMABILITY		3
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

- ACGIH : USA. ACGIH Threshold Limit Values (TLV)
- CAL PEL : California permissible exposure limits for chemical contaminants (Title 8, Article 107)
- NIOSH REL : USA. NIOSH Recommended Exposure Limits
- OSHA Z-1 : USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
- OSHA Z-3 : USA. Occupational Exposure Limits (OSHA) - Table Z-3 Mineral Dusts
- ACGIH / TWA : 8-hour, time-weighted average
- CAL PEL / PEL : Permissible exposure limit
- NIOSH REL / TWA : Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
- OSHA Z-1 / TWA : 8-hour time weighted average
- OSHA Z-3 / TWA : 8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardization; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECS - Inventory of Existing Chemical Substances in China; IMDG - International Maritime

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Islatravir / Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/09/2026
8.0	05/19/2026	3503196-00023	Date of first issue: 10/08/2018

Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organization for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorization and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 05/19/2026

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8